This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Acerus Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
Belangrijke informatie
Ed Gudaitis
Algemeen directeur
US$807.1k
Totale compensatie
| Percentage CEO-salaris | 24.7% |
| Dienstverband CEO | 4.8yrs |
| Eigendom CEO | 1.0% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 6yrs |
Recente managementupdates
Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12
The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30
Recent updates
Auditors Have Doubts About Acerus Pharmaceuticals (TSE:ASP)
Mar 14Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12Acerus Pharmaceuticals' (TSE:ASP) Shareholders Are Down 88% On Their Shares
Jan 22The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$28m |
| Jun 30 2022 | n/a | n/a | -US$29m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$807k | US$199k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$32m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$664k | US$177k | -US$24m |
| Sep 30 2020 | n/a | n/a | -US$21m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$190k | US$181k | -US$16m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$394k | US$185k | -US$19m |
Compensatie versus markt: Ed's total compensation ($USD807.09K) is above average for companies of similar size in the Canadian market ($USD172.94K).
Compensatie versus inkomsten: Ed's compensation has increased whilst the company is unprofitable.
CEO
Ed Gudaitis
4.8yrs
Tenure
US$807,086
Compensatie
Mr. Edward Gudaitis, also known as Ed, is President, Director and Chief Executive Officer at Acerus Pharmaceuticals Corp. since May 01, 2018. He is a Director for BioteCanada. Mr. Gudaitis has spent many y...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 4.8yrs | US$807.09k | 1.03% CA$ 28.6k | |
| Senior Vice President of International Commercial | 3.8yrs | US$411.98k | geen gegevens | |
| Chief Medical Officer | 2.7yrs | US$452.01k | geen gegevens | |
| Interim Chief Financial Officer | less than a year | geen gegevens | geen gegevens | |
| Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior VP | 6.7yrs | US$287.97k | 0.0046% CA$ 128.8 | |
| President of Acerus Pharmaceuticals SRL | no data | US$306.94k | geen gegevens |
3.8yrs
Gemiddelde duur
Ervaren management: ASP's management team is considered experienced (3.8 years average tenure).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 4.8yrs | US$807.09k | 1.03% CA$ 28.6k | |
| Vice Chairman | less than a year | geen gegevens | 0.032% CA$ 899.9 | |
| Chairman of the Board | 9.5yrs | US$46.15k | geen gegevens | |
| Independent Director | 11.7yrs | US$38.12k | geen gegevens | |
| Lead Independent Director | 7.3yrs | US$32.11k | 0.032% CA$ 877.4 | |
| Independent Director | 2.8yrs | US$44.01k | geen gegevens |
6.0yrs
Gemiddelde duur
69yo
Gemiddelde leeftijd
Ervaren bestuur: ASP's board of directors are considered experienced (6 years average tenure).